Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17179265 | 0.86 | PDE10A (0.45) | BACE1PDE10ATERTCYSLTR2CYSLTR1 | |
| SCHEMBL25519684 | 0.82 | PDE10A (0.50) | BACE1PDE10AHDAC1HDAC2TSHR | |
| SCHEMBL14124737 | 0.81 | HDAC1 (0.50) | BACE1PDE10AHDAC1HDAC2TSHR | |
| SCHEMBL127792 | 0.81 | BACE1 (0.53) | BACE1PDE10AHDAC1HDAC2TSHR | |
| SCHEMBL1420330 | 0.81 | BACE1 (0.53) | BACE1PDE10AHDAC1HDAC2TSHR | |
| SCHEMBL12209404 | 0.81 | BACE1 (0.53) | BACE1PDE10AHDAC1HDAC2TSHR | |
| SCHEMBL2567212 | 0.81 | BACE1 (0.53) | BACE1PDE10AHDAC1HDAC2TSHR | |
| SCHEMBL22330375 | 0.80 | BACE1 (0.49) | BACE1PDE10AHDAC1HDAC2TSHR | |
| SCHEMBL6230105 | 0.78 | CYP1A2 (0.59) | BACE1PDE3BPDE3ACYSLTR2CYSLTR1 | |
| SCHEMBL12824284 | 0.78 | CYP1A2 (0.50) | PDE10ATSHRTERTCYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5444071-A | Hypotensive agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-08-22 | — | — | US | claimed |
| EP-0412848-B1 | Quinoline derivatives, process for their preparation and their use as medicaments | ICI PLC (GB) | 1995-01-18 | — | — | EP | claimed |
| CN-1050187-A | New quinoline compound and preparation method thereof | ICI PLC (GB) | 1991-03-27 | — | — | CN | claimed |
| EP-0412848-A2 | Quinoline derivatives, process for their preparation and their use as medicaments | ZENECA LIMITED (GB) | 1991-02-13 | — | — | EP | claimed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| WO-2015154169-A1 | BINDING FUNCTION3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-10-15 | — | — | WO | disclosed |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-10-01 | — | — | US | disclosed |
| US-8481534-B2 | 5- and 6-membered heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8466148-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8323621-B2 | site-directed delivery of contrast agent; brain or breast cancer; 1,4,7,10 tetraazacyclododecane having variable chelating ions, phosphoester chains, and light harvesting moieties for changing imaging methods; conjugated to high affinity PBR ligand PK11195; bound to a PVA or a PEG delivery vehicle | VANDERBILT UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8323621-B2 | site-directed delivery of contrast agent; brain or breast cancer; 1,4,7,10 tetraazacyclododecane having variable chelating ions, phosphoester chains, and light harvesting moieties for changing imaging methods; conjugated to high affinity PBR ligand PK11195; bound to a PVA or a PEG delivery vehicle | VANDERBILT UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| EP-0470795-B1 | Process for the manufacture of nitriles | ZENECA LTD (GB) | 1995-01-25 | — | — | EP | disclosed |
| EP-0412848-B1 | Quinoline derivatives, process for their preparation and their use as medicaments | ICI PLC (GB) | 1995-01-18 | — | — | EP | disclosed |
| EP-0511347-A1 | META-SUBSTITUTED PHENYL ALANINE DERIVATIVES | Pentapharm A.G. (CH) | 1992-11-04 | — | — | EP | disclosed |
| EP-0495948-A1 | PROCESS FOR THE MANUFACTURE OF QUINOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1992-07-29 | — | — | EP | disclosed |
| WO-1992002508-A1 | PROCESS FOR THE MANUFACTURE OF QUINOLINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-20 | — | — | WO | disclosed |
| EP-0470795-A1 | Process for the manufacture of nitriles | ZENECA LIMITED (GB) | 1992-02-12 | — | — | EP | disclosed |
| EP-0470794-A1 | Process for the preparation of nitriles | ZENECA LIMITED (GB) | 1992-02-12 | — | — | EP | disclosed |
| EP-0412848-A2 | Quinoline derivatives, process for their preparation and their use as medicaments | ZENECA LIMITED (GB) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | PDE12, PDE7A, PDE10A | BACE1 48/4885PDE10A 3/4885HDAC1 180/4885 |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | BACE1 723/4885PDE10A 1526/4885HDAC1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.